FDA Grants Zumutor IND For Novel Mab ZM008 And Pembrolizumab Against Multiple Solid Cancers

Aug 11, 2023

Zumutor Biologics announced that FDA has granted its Investigational New Drug (IND) application for ZM008 (IgG1 monoclonal antibody) to initiate a phase I clinical study for the treatment of multiple solid cancers. The FDA approved the use of a staggered parallel clinical design for the combination of ZM008 and pembrolizumab which could benefit a wider range of patients whose immune response could be boosted with ZM008.

Print Page Mail Article